摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

benzo[b]thiophen-2-yl-(2,3-dimethyl-furan-5-yl)-methane | 264254-46-8

中文名称
——
中文别名
——
英文名称
benzo[b]thiophen-2-yl-(2,3-dimethyl-furan-5-yl)-methane
英文别名
5-(1-benzothiophen-2-ylmethyl)-2,3-dimethylfuran
benzo[b]thiophen-2-yl-(2,3-dimethyl-furan-5-yl)-methane化学式
CAS
264254-46-8
化学式
C15H14OS
mdl
——
分子量
242.342
InChiKey
FXEVTBUDUBOKNX-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.8
  • 重原子数:
    17
  • 可旋转键数:
    2
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.2
  • 拓扑面积:
    41.4
  • 氢给体数:
    0
  • 氢受体数:
    2

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    对甲氧基苯甲酰氯benzo[b]thiophen-2-yl-(2,3-dimethyl-furan-5-yl)-methane四氯化锡 作用下, 以 二硫化碳 为溶剂, 以25%的产率得到4-(2,3-dimethyl-1-oxa-9-thia-cyclopenta[b]fluoren-4-yl)-phenyl methyl ether
    参考文献:
    名称:
    4-aryl-1-oxa-9-thia-cyclopenta[b]fluorenes
    摘要:
    本发明提供了具有结构式I的化合物,其中B和D分别独立地为氢、卤素、--CN、1-6个碳原子的烷基、芳基或6-12个碳原子的芳基烷基;R1为氢、1-6个碳原子的烷基、--CH(R2)W、--C(CH3)2CO2R3、5-噻唑烷-2,4-二酮、--CH(R4)CH2CO2R3、--COR3或--PO3(R3)2;R2为氢、1-6个碳原子的烷基、6-12个碳原子的芳基烷基、芳基、--CH2(1H-咪唑-4-基)、--CH2(3-1H-吲哚基)、--CH2CH2(1,3-二氢异吲哚-2-基)、--CH2CH2(1-氧代-1,3-二氢异吲哚-2-基)或--CH2(3-吡啶基);W为--CO2R3、--CONH2、--CONHOH、--CN、CONH(CH2)2CN、5-四唑或--PO3(R3)2;R3为氢、1-6个碳原子的烷基或芳基;R4为氢或1-6个碳原子的烷基;或其药学上可接受的盐,其用于治疗与胰岛素抵抗或高血糖相关的代谢障碍。
    公开号:
    US06057316A1
  • 作为产物:
    描述:
    4,5-二甲基-2-糠醛 在 sodium tetrahydroborate 、 正丁基锂三氟乙酸 作用下, 以 四氢呋喃 为溶剂, 反应 4.5h, 生成 benzo[b]thiophen-2-yl-(2,3-dimethyl-furan-5-yl)-methane
    参考文献:
    名称:
    Synthesis and PTP1B Inhibition of Novel 4-Aryl-1-Oxa-9-Thiacyclopenta[b]fluorenes
    摘要:
    Novel 4-aryl-1-oxa-9-thiacyclopenta[b]fluorenes were designed, synthesized, and evaluated as inhibitors of the protein tyrosine phosphatase, PTP1B. Compounds 3 (IC50 = 284 nM) and 4 (IC50 = 74 nM), showed nanomolar potency against PTP1B (TRDI(P)YETD(P)Y(P)YRK as substrate). Compound 4 also lowered insulin in the diabetic ob/ob mouse at a dose of 10 mg/kg/day, po. (C) 2000 Elsevier Science Ltd. All rights reserved.
    DOI:
    10.1016/s0960-894x(00)00278-x
点击查看最新优质反应信息

文献信息

  • 4-aryl-1-oxa-9-thia-cyclopenta[b]fluorenes
    申请人:American Home Products Corporation
    公开号:US06057316A1
    公开(公告)日:2000-05-02
    This invention provides compounds of Formula I having the structure ##STR1## wherein B and D are each, independently, hydrogen, halogen, --CN, alkyl of 1-6 carbon atoms, aryl, or aralkyl of 6-12 carbon atoms; R.sup.1 is hydrogen, alkyl of 1-6 carbon atoms, --CH(R.sup.2)W, --C(CH.sub.3).sub.2 CO.sub.2 R.sup.3, 5-thiazolidine-2,4-dione, --CH(R.sup.4)CH.sub.2 CO.sub.2 R.sup.3, --COR.sup.3, or --PO.sub.3 (R.sup.3).sub.2 ; R.sup.2 is hydrogen, alkyl of 1-6 carbon atoms, aralkyl of 6-12 carbon atoms, aryl, --CH.sub.2 (1H-imidazol-4-yl), --CH.sub.2 (3-1H-indolyl), --CH.sub.2 CH.sub.2 (1,3-dioxo-1,3-dihydro-isoindol-2-yl), --CH.sub.2 CH.sub.2 (1-oxo-1,3-dihydro-isoindol-2-yl), or --CH.sub.2 (3-pyridyl); W is --CO.sub.2 R.sup.3, --CONH.sub.2, --CONHOH, --CN, CONH(CH.sub.2).sub.2 CN, 5-tetrazole, or --PO.sub.3 (R.sup.3).sub.2 ; R.sup.3 is hydrogen, alkyl of 1-6 carbon atoms, or aryl; R.sup.4 is hydrogen or alkyl of 1-6 carbon atoms; or a pharmaceutically acceptable salt thereof, which are useful in treating metabolic disorders related to insulin resistance or hyperglycemia.
    本发明提供了具有结构式I的化合物,其中B和D分别独立地为氢、卤素、--CN、1-6个碳原子的烷基、芳基或6-12个碳原子的芳基烷基;R1为氢、1-6个碳原子的烷基、--CH(R2)W、--C(CH3)2CO2R3、5-噻唑烷-2,4-二酮、--CH(R4)CH2CO2R3、--COR3或--PO3(R3)2;R2为氢、1-6个碳原子的烷基、6-12个碳原子的芳基烷基、芳基、--CH2(1H-咪唑-4-基)、--CH2(3-1H-吲哚基)、--CH2CH2(1,3-二氢异吲哚-2-基)、--CH2CH2(1-氧代-1,3-二氢异吲哚-2-基)或--CH2(3-吡啶基);W为--CO2R3、--CONH2、--CONHOH、--CN、CONH(CH2)2CN、5-四唑或--PO3(R3)2;R3为氢、1-6个碳原子的烷基或芳基;R4为氢或1-6个碳原子的烷基;或其药学上可接受的盐,其用于治疗与胰岛素抵抗或高血糖相关的代谢障碍。
  • 4-aryl-1-oxa-9-thia-cyclopenta (b) fluorenes
    申请人:American Home Products Corporation
    公开号:US06340676B2
    公开(公告)日:2002-01-22
    This invention provides compounds of Formula I having the structure wherein B and D are each, independently, hydrogen, halogen, —CN, alkyl of 1-6 carbon atoms, aryl, or aralkyl of 6-12 carbon atoms; R1 is hydrogen, alkyl of 1-6 carbon atoms, —CH(R2)W, —C(CH3)2CO2R3, 5-thiazolidine-2,4-dione, —CH(R4)CH2CO2R3, —COR3, or —PO3(R3)2; R2 is hydrogen, alkyl of 1-6 carbon atoms, aralkyl of 6-12 carbon atoms, aryl, —CH2(1H-imidazol-4-yl), —CH2(3-1H-indolyl), —CH2CH2(1,3-dioxo-1,3-dihydro-isoindol-2-yl), —CH2CH2(1-oxo-1,3-dihydro-isoindol-2-yl), or —CH2(3-pyridyl); W is —CO R3, —CONH2, —CONHOH, —CN, CONH(CH2)2CN, 5-tetrazole, or —PO3(R3)2; R3 is hydrogen, alkyl of 1-6 carbon atoms, or aryl; R4 is hydrogen or alkyl of 1-6 carbon atoms; or a pharmaceutically acceptable salt thereof, which are useful in treating metabolic disorders related to insulin resistance or hyperglycemia.
    该发明提供了具有结构式I的化合物,其中B和D分别独立地为氢、卤素、—CN、1-6个碳原子的烷基、芳基或6-12个碳原子的芳基烷基;R1为氢、1-6个碳原子的烷基、—CH(R2)W、—C(CH3)2CO2R3、5-噻唑烷-2,4-二酮、—CH(R4)CH2CO2R3、—COR3或—PO3(R3)2;R2为氢、1-6个碳原子的烷基、6-12个碳原子的芳基烷基、芳基、—CH2(1H-咪唑-4-基)、—CH2(3-1H-吲哚基)、—CH2CH2(1,3-二氢-异吲哚-2-基-1,3-二酮)、—CH2CH2(1-氧代-1,3-二氢-异吲哚-2-基-1,3-二酮)或—CH2(3-吡啶基);W为—CO R3、—CONH2、—CONHOH、—CN、CONH(CH2)2CN、5-四唑或—PO3(R3)2;R3为氢、1-6个碳原子的烷基或芳基;R4为氢或1-6个碳原子的烷基;或其药学上可接受的盐,用于治疗与胰岛素抵抗或高血糖相关的代谢性疾病。
  • 4-aryl-1-oxa-9-thia-cylopenta[B]fluorenes
    申请人:American Home Products Corporation
    公开号:US06281238B1
    公开(公告)日:2001-08-28
    This invention provides compounds of Formula I having the structure wherein B and D are each, independently, hydrogen, halogen, —CN, alkyl of 1-6 carbon atoms, aryl, or aralkyl of 6-12 carbon atoms; R1 is hydrogen, alkyl of 1-6 carbon atoms, —CH(R2)W, —C(CH3)2CO2R3, 5-thiazolidine-2,4-dione, —CH(R4)CH2CO2R3, —COR3, or —PO3(R3)2; R2 is hydrogen, alkyl of 1-6 carbon atoms, aralkyl of 6-12 carbon atoms, aryl, —CH2(1H-imidazol-4-yl), —CH2(3-1H-indolyl), —CH2CH2(1,3-dioxo-1,3-dihydro-isoindol-2-yl), —CH2CH2(1-oxo-1,3-dihydro-isoindol-2-yl), or —CH2(3-pyridyl); W is —CO2R3, —CONH2, —CONHOH, —CN, CONH(CH2)2CN, 5-tetrazole, or —PO3(R3)2; R3 is hydrogen, alkyl of 1-6 carbon atoms, or aryl; R4 is hydrogen or alkyl of 1-6 carbon atoms; or a pharmaceutically acceptable salt thereof, which are useful in treating metabolic disorders related to insulin resistance or hyperglycemia.
    本发明提供了具有结构式I的化合物,其中B和D分别是氢、卤素、—CN、1-6个碳原子的烷基、芳基或6-12个碳原子的芳基烷基;R1是氢、1-6个碳原子的烷基、—CH(R2)W、—C(CH3)2CO2R3、5-噻唑烷-2,4-二酮、—CH(R4)CH2CO2R3、—COR3或—PO3(R3)2;R2是氢、1-6个碳原子的烷基、6-12个碳原子的芳基烷基、芳基、—CH2(1H-咪唑-4-基)、—CH2(3-1H-吲哚基)、—CH2CH2(1,3-二氢-异吲哚-2-基)-1,3-二酮、—CH2CH2(1-氧-1,3-二氢-异吲哚-2-基)-1,3-二酮或—CH2(3-吡啶基);W是—CO2R3、—CONH2、—CONHOH、—CN、CONH(CH2)2CN、5-四唑或—PO3(R3)2;R3是氢、1-6个碳原子的烷基或芳基;R4是氢或1-6个碳原子的烷基;或其药学上可接受的盐,用于治疗与胰岛素抵抗或高血糖相关的代谢性疾病。
  • US6057316A
    申请人:——
    公开号:US6057316A
    公开(公告)日:2000-05-02
  • US6281238B1
    申请人:——
    公开号:US6281238B1
    公开(公告)日:2001-08-28
查看更多

同类化合物